South Lincoln Dialysis is a medicare approved dialysis facility center in Lincoln, Nebraska and it has 8 dialysis stations. It is located in Lancaster county at 3401 Plantation Drive Suite 140, Lincoln, NE, 68516. You can reach out to the office of South Lincoln Dialysis at (402) 421-6011. This dialysis clinic is managed and/or owned by Davita. South Lincoln Dialysis has the following ownership type - Profit. It was first certified by medicare in May, 2006. The medicare id for this facility is 282526 and it accepts patients under medicare ESRD program.
| Name | South Lincoln Dialysis |
|---|---|
| Location | 3401 Plantation Drive Suite 140, Lincoln, Nebraska |
| No. of Dialysis Stations | 8 |
| Medicare ID | 282526 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 3401 Plantation Drive Suite 140, Lincoln, Nebraska, 68516 | |
| (402) 421-6011 | |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
| NPI Number | 1396838991 |
| Organization Name | South Lincoln Dialysis |
| Doing Business As | Renal Treatment Centers Illinois Inc |
| Address | 3401 Plantation Drive Lincoln, Nebraska, 68516 |
| Phone Number | (402) 421-6011 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 12 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 8 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 22 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 159 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at South Lincoln Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 23 |
| Hypercalcemia patient months | 171 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 25 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 42 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 26 |
| Patient months included in arterial venous fistula and catheter summaries | 156 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 63 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 20 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 21 |
| Hospitalization Rate in facility | 109.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 358.5 |
| Hospitalization Rate: Lower Confidence Limit | 37 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at South Lincoln Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 50 |
| Readmission Rate: Lower Confidence Limit | 11.7 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
An investigational parathyroid hormone replacement effectively treated a rare disorder characterized by low calcium and high phosphate levels in the blood, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.
ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes
A paper by Indiana University-Purdue University Indianapolis researchers describing the development of a new methodology to improve identification of breast cancer tissue by pathology laboratories has been selected as the best scientific paper in the "bioinformatics and biomedical applications track" by the International Association for Pattern Recognition.
› Verified 5 days ago